Clinical Trial Update: GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating GKL-006 in combination with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• GKL-006

Snippet

Sponsor: Beijing Gene Key Life Technology Co., Ltd | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING